Potent in vivo anti-tumor activity of isolated CD62Llow lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines

DC-based VDLN T cells are an important source of anti-tumor effector for adoptive immunotherapy. This study provides a novel and an effective protocol using T-cell adoptive immunotherapy for application in cancer patients; therefore, clinical trials based on this protocol may be warranted.